Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Imlygic Coverage & Prior Auth Update | Open…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0135

    Melanoma Vaccines (Imlygic/talimogene laherparepvec)

    Customize your policy alerts

    Sign up for Anthem Policy CC-0135 alerts

    Get alerted when Policy CC-0135 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for use of Imlygic (talimogene laherparepvec) and other melanoma vaccines under the medical benefit for members; applies to coverage decisions for melanoma and select Merkel cell carcinoma indications.

    Policy Summary
    PayerAnthem
    PolicyMelanoma Vaccines (Imlygic/talimogene laherparepvec)
    Policy CodePolicy CC-0135
    Change TypeMaterial criteria and coding updates
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documented diagnosis, disease stage, lesion accessibility for intralesional therapy, prior treatments, and confirmation the patient is not immunocompromised or pregnant.
    SourceLink
    POLICY UPDATE CHANGES

    Updated per NCCN 2A for Merkel cell carcinoma intralesional treatment for primary N+ M0 disease or recurrent N+ regional disease if curative surgery and curative RT are not feasible.

    Wording and formatting criteria updates; criteria aligned with NCCN 2A language and inclusion of oligometastatic and widely disseminated disease per NCCN.

    Removed HCPCS NOC J3590 from coding list.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1FDA-approved melanoma vaccine (Imlygic)
    J9325Billing HCPCS
    C43.xMelanoma ICD-10
    C4A.xMerkel cell ICD-10

    Coverage Criteria for Imlygic and Melanoma Vaccines

    Initial Therapy — Requests for Imlygic may be approved when the following criteria are met:

    Requests for Imlygic may be approved when ALL of the following are met:

    Age or diagnosis

    • Melanoma intralesional indication: Individual is using for limited resectable or unresectable disease as intralesional treatment for one of: A. Stage III disease with clinical satellite/in-transit metastases; OR B. Stage III clinically positive node(s); OR C. Local satellite/in-transit recurrence of disease; OR D. Nodal recurrence of disease

      NCCN 2A; efficacy greater in less advanced, treatment-naïve patients

    • Advanced disease indications: Individual is using as intralesional treatment of accessible lesions in oligometastatic disease OR as intralesional treatment of limited extracranial lesions in widely disseminated distant metastatic disease

      NCCN 2A

    • Merkel cell carcinoma indications: Individual has a diagnosis of Merkel cell carcinoma AND meets one of: A. Intralesional treatment for primary N+, M0 regional disease or recurrent N+ regional disease if curative surgery and curative radiation therapy (RT) are not feasible, but not M1 disseminated disease; OR B. Intralesional treatment for in-transit primary N+ regional disease if curative surgery and/or RT are not feasible

      NCCN 2A; added per 02/20/2026 update

    • Agent and exclusions: Individual is using Imlygic (talimogene laherparepvec) as a single agent; Exclusions: all other indications not included above; immunocompromised individuals; pregnant individuals

      Imlygic is contraindicated in immunocompromised and pregnant patients per package insert

    Agent requirement: Individual is using Imlygic (talimogene laherparepvec) as a single agent for intralesional therapy

    Policy specifies single-agent use

    Requests for Imlygic (talimogene laherparepvec) should not be approved for indications outside those specified in the policy. Specifically, coverage is excluded for: (1) all other indications not included above; (2) individuals who are immunocompromised; and (3) individuals who are pregnant.

    Use of melanoma vaccines other than talimogene laherparepvec is not approved and is considered not medically necessary under this policy.

    Covered Regimens and Dosing

    RegimenIndicationBilling HCPCSCoverage
    Imlygic (talimogene laherparepvec) intralesional injectionsIntralesional single-agent therapy for specified melanoma and Merkel cell carcinoma indications: unresectable or borderline resectable stage III disease with clinical satellite/in-transit metastases or clinically positive node(s); limited resectable or unresectable local/regional recurrence; nodal recurrence; intralesional treatment of accessible lesions in oligometastatic disease or limited extracranial lesions in widely disseminated metastatic disease; Merkel cell carcinoma primary N+, M0 regional disease or recurrent N+ regional disease or in-transit primary N+ regional disease when curative surgery and/or radiation are not feasible (not for M1 disseminated disease). See coverage criteria for full details and exclusions (immunocompromised or pregnant individuals excluded).J9325 — Injection, talimogene laherparepvec, per 1 million plaque forming unitsCovered

    Billing and Diagnosis Codes

    HCPCSHCPCSCovered
    J9325Injection, talimogene laherparepvec, per 1 million plaque forming units [Imlygic]
    ICD-10 DiagnosisICD-10
    C43.0-C43.9Malignant melanoma of skin
    C4A.0-C4A.9Merkel cell carcinoma

    Provider Actions: Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization required: Requests for Imlygic (talimogene laherparepvec) must be prior authorized and meet the plan's clinical criteria for approved indications. Approval is limited to the specific covered indications and patient populations; requests for all other indications will not be approved.

    • Imlygic (talimogene laherparepvec) prior authorization required
    • Approval limited to covered indications and populations; see documentation requirements below
    • Requests for Imlygic will be denied if patient is immunocompromised or pregnant
    Step Therapy

    Step Therapy

    No step therapy (no requirement to try other systemic agents before Imlygic) is imposed by this policy. The policy references clinical trial comparators (e.g., subcutaneous GM-CSF) for context but does not mandate trials of other agents prior to Imlygic use.

    Definitions and Key Terms

    In-transit metastasis — definition
    DefinitionIn-transit metastasis: intralymphatic tumor in skin or subcutaneous tissue more than 2 cm from the primary tumor but not beyond the nearest regional lymph node basin; includes microsatellites, clinically evident satellites, and regional in-transit disease.
    Anatomic scopeLesions are confined to skin or subcutaneous tissue and do not extend beyond the nearest regional lymph node basin.
    Clinical significancePart of the biologic continuum of regional lymphatic involvement and associated with a prognosis similar to clinically positive nodes (staging designation e.g., stage IIIC).
    Examples includedMicrosatellites, clinically evident satellites, and regional in-transit disease are encompassed by this definition.
    Durable response rate (DRR) — definition
    Definition

    Background

    Therapeutic melanoma vaccines are intended to stimulate anti-tumor immune responses by presenting tumor-associated antigens to the immune system. Imlygic (talimogene laherparepvec) is an FDA-approved intralesional oncolytic herpes simplex virus type 1 engineered to express GM-CSF for local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions that recur after surgery. Clinical trials demonstrated an improvement in durable response rate (DRR) but not overall survival, with greater benefit observed in less advanced, treatment‑naïve disease. Definitions relevant to interpretation include in-transit metastasis (intralymphatic tumor in skin or subcutaneous tissue more than 2 cm from the primary tumor but not beyond the nearest regional lymph node basin) and DRR (complete or partial responses lasting > 6 months and beginning within the first 12 months).

    Line of Therapy

    Line of Therapy

    Line of therapy decision:

    Line of therapy: Intralesional Imlygic is indicated for unresectable or borderline resectable stage III disease, limited resectable or unresectable local/regional recurrences, oligometastatic disease, and limited extracranial lesions in widely disseminated metastatic disease per NCCN category 2A; greater efficacy is observed in less advanced, treatment‑naïve patients.

    NCCN 2A recommendations

    Revision History

    02/20/2026Annual review / material updateLatest

    Wording and formatting updates to criteria; added NCCN 2A recommendation for intralesional Merkel cell carcinoma for primary N+ M0 or recurrent N+ regional disease when curative surgery and curative RT are not feasible; coding reviewed and HCPCS NOC J3590 removed.

    02/21/2025Annual review / coding update

    Added NCCN recommendation for use in Merkel cell carcinoma; coding reviewed and ICD-10-CM C4A.0-C4A.9 added.

    02/23/2024
    Policy Summary
    PayerAnthem
    PolicyMelanoma Vaccines (Imlygic/talimogene laherparepvec)
    Policy CodePolicy CC-0135
    Change TypeMaterial criteria and coding updates
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documented diagnosis, disease stage, lesion accessibility for intralesional therapy, prior treatments, and confirmation the patient is not immunocompromised or pregnant.
    SourceLink
    On This Page
    Coverage Criteria for Imlygic and Melanoma VaccinesCovered Regimens and DosingBilling and Diagnosis CodesProvider Actions: Prior Authorization, Documentation, and Denial RisksDefinitions and Key TermsBackgroundLine of TherapyRevision History
  1. No prerequisite trial of other systemic therapies required prior to Imlygic under this policy
  2. Clinical-trial comparators are informational only and not step therapy requirements
  3. Documentation Required

    Required Documentation

    Required documentation for prior authorization: submit diagnosis (melanoma or Merkel cell carcinoma), disease stage, description of lesion accessibility and location, statement that Imlygic will be used as intralesional single-agent therapy, and justification that surgery and/or radiation are not feasible when applicable. Also document age if <19 years (pediatric approval pathway) and confirm patient is not immunocompromised or pregnant.

    • Diagnosis: melanoma or Merkel cell carcinoma
    • Disease stage and clinical scenario (e.g., stage III with in-transit/satellite metastases, nodal recurrence, oligometastatic or limited extracranial lesions)
    • Lesion accessibility and intralesional treatment plan
    • Confirmation Imlygic used as single agent
    • If applicable, documentation that curative surgery and/or radiation are not feasible
    • Patient not immunocompromised and not pregnant
    • Age documentation if patient is <19 years
    Denial Risk

    Common Denial Triggers

    Common denial triggers: requests for melanoma vaccines other than Imlygic, use in immunocompromised or pregnant patients, use for indications not listed in the coverage criteria (including M1 disseminated disease outside the limited extracranial/oligometastatic contexts), or use in combination with other systemic agents.

    • Requests for non‑Imlygic melanoma vaccines — not approved
    • Use in immunocompromised patients — contraindicated and will be denied
    • Use in pregnant patients — contraindicated and will be denied
    • Use for indications not enumerated in the coverage criteria (e.g., general metastatic M1 disease not meeting limited lesion criteria)
    • Requests for Imlygic in combination with other systemic anticancer agents — not approved under this policy
    Durable response rate (DRR): rate of complete response (CR) plus partial response (PR) lasting > 6 months continuously and beginning within the first 12 months.
    Timeframe requirementResponse duration must exceed 6 continuous months and must start within the first 12 months after treatment initiation.
    ComponentsIncludes both complete responses and partial responses when the duration and timing criteria are met.
    Endpoint useUsed as a primary efficacy endpoint in trials of Imlygic to assess sustained tumor responses.
    Annual review

    Updated criteria to align with NCCN wording and to include oligometastatic and widely disseminated disease per NCCN; coding reviewed with no changes.

    02/24/2023Annual review

    Annual review documented with no clinical changes and coding reviewed with no changes.

    02/25/2022Annual review

    Annual review documented with no clinical changes and coding reviewed with no changes.

    02/19/2021Annual review

    Annual review documented with no clinical changes and coding reviewed with no changes.

    02/21/2020Annual review

    Wording and formatting changes for clarity; added 'may not be approved' criteria for immunocompromised and pregnant patients; coding reviewed with no changes.

    05/17/2019Annual review (initial)

    First review of Melanoma Vaccines clinical criteria; no clinical changes and coding reviewed with no changes.